- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Ovarian cancer
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 817KB)
Olaparib – July 2022
Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza®
Last updated
30 May 2025